Validating blood microsampling for per- and polyfluoroalkyl substances quantification in whole blood
Partington et al.
The finding, in our words
Filtered protein precipitation was the most effective extraction method for 75 per- and polyfluoroalkyl substances from dried blood spots collected with a capillary microsampler, recovering 72 analytes within 70–130% with limits of detection from 0.05 to 0.34 ng/mL. The method detected 16 PFAS in self-collected human samples, demonstrating feasibility for large-scale biomonitoring studies using minimally invasive sampling.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
In AML and CLL, 91% of VAMS venetoclax results fell within 20% of plasma after individualised haematocrit correction; in home sampling, 18 of 21 patients self-sampled independently and 76% of returned samples were analysable, which shows home microsampling is workable, though the authors ask for multicentre validation.
This review found that volumetric microsampling devices, such as Mitra, HemaPEN, HemaXis DB10, and Tasso-M20, overcome haematocrit bias, whilst Telimmune plasma separation cards enable direct plasma collection without centrifugation. These technologies support patient-centric, decentralised sampling, though the authors note that clinical validation remains limited across different drugs and patient populations.
Capillary dried blood spots, after haematocrit-dependent conversion, showed good agreement with plasma for 25-hydroxyvitamin D quantification, with 90 per cent of results within 20 per cent of plasma and substantial to almost perfect agreement in status classification, supporting reliable home self-collection for large-scale vitamin D monitoring.
The study validated a semi-quantitative protocol for Epstein-Barr virus serology using dried blood spots, demonstrating 98.8% sensitivity and 96.5% specificity compared to paired venous serum samples. The successful validation in a self-sampling cohort confirms the suitability of this patient-centric microsampling approach for large-scale seroprevalence studies and decentralised trials.
A validated two-step LC-MS/MS protocol can identify 91 prohibited doping agents from a single dried blood spot collected on either cellulose cards or volumetric absorptive microsampling devices. This demonstrates robust multi-analyte screening from capillary blood, supporting decentralised anti-doping programmes where venous sampling is impractical.